Q32 Bio to Participate in the 2026 Jefferies Global Healthcare Conference in London
PR Newswire•11/11/2026•06:59 ET
0
Key Highlights
- ➤Q32 Bio (QTTB) management to participate in a November 18 Jefferies healthcare conference fireside chat
- ➤Webcast and 90-day archived replay will be available on Q32 Bio’s website
- ➤Q32 Bio advances bempikibart (ADX-914) in an ongoing Phase 2 alopecia areata program
Q32 Bio to Participate in the 2026 Jefferies Global Healthcare Conference in London PR Newswire
WALTHAM, Mass., Nov. 11, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical-stage biotechnology company focused on developing innovative therapies for alopecia areata ("AA") and other autoimmune and inflammatory diseases, today announced that management will participate in a fireside chat at 12 p.m. GMT (7 a.m. ET) on Wednesday, November 18, 2026 at the 2026 Jefferies Global Healthcare Conference in London.
Get started
Create a free account to read the full story.